Gilead Announces Approval of Veklury® (remdesivir) in Japan for Patients With Severe COVID-19

Gilead Sciences, Inc. announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval of Veklury® (remdesivir) as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19, under an exceptional approval pathway. The exceptional approval was granted due to the COVID-19 pandemic and references the Emergency Use Authorization of remdesivir in the United States.

source https://www.pharmatutor.org/pharma-news/2020/gilead-announces-approval-of-veklury-remdesivir-in-japan-for-patients-with-severe-covid-19